A Benefit-Risk Analysis Approach to Capture Regulatory Decision-Making: Multiple Myeloma

Drug regulators around the world make decisions about drug approvability based on qualitative benefit-risk analysis. In this work, a quantitative benefit-risk analysis approach captures regulatory decision-making about new drugs to treat multiple myeloma (MM). MM assessments have been based on endpo...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Pharmacol Ther
Päätekijät: Raju, G.K., Gurumurthi, Karthik, Domike, Reuben, Kazandjian, Dickran, Landgren, Ola, Blumenthal, Gideon M., Farrell, Ann, Pazdur, Richard, Woodcock, Janet
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2017
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7418461/
https://ncbi.nlm.nih.gov/pubmed/28901535
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.871
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia